DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

5DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Sel24-b489, Sel-24 free base, 9m7x64vtli, Sel24-b289, 1616359-00-2, 1h-benzimidazole, 5,6-dibromo-1-(1-methylethyl)-4-nitro-2-(4-piperidinyl)-

Molecular Formula

C₁₅H₁₈Br₂N₄O₂

Molecular Weight

446.14 g/mol

InChI Key

UOUBCIJIWDLRGM-UHFFFAOYSA-N

FDA UNII

9M7X64VTLI

PIM/FLT3 Kinase Inhibitor SEL24 is an orally available inhibitor of PIM family serine/threonine protein kinases and mutant forms of FMS-related tyrosine kinase 3 (FLT3; STK1) with potential antineoplastic activity. PIM/FLT3 kinase inhibitor SEL24 binds to and inhibits the kinase activities of PIM-1, -2 and -3, and mutant forms of FLT3, which may result in the interruption of the G1/S phase cell cycle transition, an inhibition of cell proliferation, and an induction of apoptosis in tumor cells that overexpress PIMs or express mutant forms of FLT3. FLT3, a tyrosine kinase receptor that is overexpressed or mutated in various cancers, plays a role in signaling pathways that regulate hematopoietic progenitor cell proliferation, and in leukemic cell proliferation and survival. PIM kinases, downstream effectors of many cytokine and growth factor signaling pathways, including the FLT3 signaling pathway, play key roles in cell cycle progression and apoptosis inhibition and may be overexpressed in various malignancies.

1 2D Structure

MEN1703

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

5,6-dibromo-4-nitro-2-piperidin-4-yl-1-propan-2-ylbenzimidazole

2.1.2 InChI

InChI=1S/C15H18Br2N4O2/c1-8(2)20-11-7-10(16)12(17)14(21(22)23)13(11)19-15(20)9-3-5-18-6-4-9/h7-9,18H,3-6H2,1-2H3

2.1.3 InChI Key

UOUBCIJIWDLRGM-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(C)N1C2=CC(=C(C(=C2N=C1C3CCNCC3)[N+](=O)[O-])Br)Br

2.2 Other Identifiers

2.2.1 UNII

9M7X64VTLI

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. Sel24-b489

2. Sel-24 Free Base

3. 9m7x64vtli

4. Sel24-b289

5. 1616359-00-2

6. 1h-benzimidazole, 5,6-dibromo-1-(1-methylethyl)-4-nitro-2-(4-piperidinyl)-

7. 5,6-dibromo-1-(1-methylethyl)-4-nitro-2-(4-piperidinyl)-1h-benzimidazole

8. 5,6-dibromo-4-nitro-2-(piperidin-4-yl)-1-(propan-2-yl)-1h-1,3-benzimidazole

9. Unii-9m7x64vtli

10. Chembl4467168

11. Schembl15826208

12. Hy-120758

13. Cs-0079085

2.4 Create Date

2014-07-28

3 Chemical and Physical Properties

Molecular Formula	C₁₅H₁₈Br₂N₄O₂
Molecular Weight	446.14 g/mol
XLogP3	3.5
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	2
Exact Mass	445.97760 g/mol
Monoisotopic Mass	443.97965 g/mol
Topological Polar Surface Area	75.7 Å²
Heavy Atom Count	23
Formal Charge	0
Complexity	442
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1